Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avalo Therapeutics, Inc. - Common Stock (NQ:AVTX)

19.52 +0.27 (+1.38%)
Streaming Delayed Price Updated: 10:11 AM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avalo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug ↗
Retail chatter around Avalo rose ahead of an Oppenheimer conference call set to discuss its lead hidradenitis suppurativa drug, AVTX-009, now in a mid-stage trial with topline results expected in... 
Via Stocktwits
News headline image
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Wondering what's happening in today's pre-market session? ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million. 
Via Benzinga
News headline image
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket ↗
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its... 
Via Benzinga
News headline image
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside ↗
Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target. 
Via Benzinga
News headline image
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Avalo Reports 2024 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
News headline image
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Present at Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.